Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Supply, Demand and Key Producers, 2026-2032
The global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market size is expected to reach $ 68.94 million by 2032, rising at a market growth of 17.1% CAGR during the forecast period (2026-2032).
Ligand precursors for Ac 225 labeled PSMA targeted radiopharmaceuticals are high purity small molecule precursor materials used to manufacture prostate specific membrane antigen targeted alpha radiotherapeutics. The research scope focuses on non radioactive ligand compounds, clinical grade precursors and GMP grade precursors that can be chelated and labeled with actinium 225 for radiopharmaceutical production. These products are generally built from a PSMA binding motif, a molecular linker, a metal chelator and a radiolabeling ready functional structure. Main product forms include lyophilized precursor powder, standardized vial based precursor materials, custom synthesized intermediates and clinical batch precursors. Their production process involves multistep organic synthesis, peptide or peptidomimetic structure construction, chelator conjugation, impurity profiling, preparative purification, low bioburden control, stability testing and GMP documentation. Key specifications usually include chemical purity, individual impurity limits, residual solvents, water content, endotoxin, metal impurities, radiolabeling yield, radiochemical purity, identity confirmation and batch to batch consistency. The core function of these precursors is to provide nuclear medicine developers, radiopharmaceutical CDMOs, clinical research institutions and hospital nuclear medicine centers with reproducible and regulatory supportable starting materials for PSMA targeted alpha therapy manufacturing. Main applications are concentrated in clinical development and early commercial validation of targeted alpha radiopharmaceuticals for PSMA positive tumors, especially metastatic castration resistant prostate cancer. In 2025, the global average gross margin of ligand precursors for Ac 225 labeled PSMA targeted radiopharmaceuticals is estimated at about 55%.
Ligand precursors for Ac 225 labeled PSMA targeted radiopharmaceuticals represent a highly specialized upstream material segment within the radiopharmaceutical value chain. The upstream side includes actinium 225 radioisotope supply, chelators, protected amino acids, peptide synthesis inputs, GMP grade solvents and high purity reagents. The midstream layer covers PSMA ligand design, precursor synthesis, purification, analytical characterization, process scale up and clinical batch preparation. The downstream side consists of radiopharmaceutical developers, nuclear medicine CDMOs, hospital nuclear medicine centers and oncology clinical research networks. This product category should not be interpreted as a general research reagent or as a final therapeutic radiopharmaceutical. Its commercial value is concentrated in regulatory grade quality control, labeling compatibility with Ac 225, impurity management, stability data and the ability to support repeatable clinical manufacturing. Since Ac 225 PSMA targeted alpha therapy is still moving through clinical development, demand is currently driven mainly by GMP validation batches, clinical trial supply, custom synthesis and equivalent in house consumption by drug developers, rather than by full commercial scale drug manufacturing.
The competitive landscape remains narrow and concentrated. Only a small number of global suppliers can be reasonably identified as actual manufacturers of PSMA radioligand precursors with relevant production evidence, while a broader group of pharmaceutical companies and nuclear medicine platforms should be treated as pipeline owners rather than precursor manufacturers. Europe and the United States are the most important supply regions, supported by established radiopharmaceutical chemistry, GMP manufacturing know how and clinical trial infrastructure. China, Japan, South Korea and India have growing capabilities in peptide synthesis, pharmaceutical CDMO services and nuclear medicine development, but public evidence for stable production of Ac 225 compatible PSMA ligand precursors remains limited. Competition is less about bulk capacity and more about GMP readiness, analytical documentation, batch reproducibility, customer project linkage and intellectual property around ligand and chelator structures. Recent mergers and acquisitions in the radiopharmaceutical sector have strengthened the strategic importance of upstream precursor control and are gradually increasing clinical batch demand.
The policy environment is generally supportive, as major healthcare markets continue to encourage nuclear medicine, targeted radiotherapy, medical isotope supply and precision oncology infrastructure. However, the industry is still constrained by limited Ac 225 availability, radiopharmaceutical manufacturing licenses, transport restrictions, clinical development timelines and regulatory uncertainty. Future growth will mainly come from three sources: the advancement of PSMA targeted alpha therapy pipelines into later clinical stages, the gradual expansion of isotope supply that enables early commercial validation, and the development of next generation PSMA ligands with improved chelation stability, tumor retention and manufacturability. The market should therefore be viewed as a small scale but high value emerging segment. In the near term, it should not be benchmarked against the broader radiopharmaceutical drug market, but over the medium to long term it has strong strategic value because precursor quality, process reliability and supply security can directly affect clinical progress and commercialization readiness.
This report studies the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals total production and demand, 2021-2032, (kg)
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals total production value, 2021-2032, (USD Million)
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (kg), (based on production site)
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals consumption by region & country, CAGR, 2021-2032 & (kg)
U.S. VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals domestic production, consumption, key domestic manufacturers and share
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (kg)
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals production by Form, production, value, CAGR, 2021-2032, (USD Million) & (kg)
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals production by Application, production, value, CAGR, 2021-2032, (USD Million) & (kg)
This report profiles key players in the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ABX Advanced Biochemical Compounds GmbH, Radnostix, Inc., JPT Peptide Technologies GmbH, SCINTOMICS Molecular, Applied Theranostics Technologies GmbH, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (kg) and average price (US$/kg) by manufacturer, by Form, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market, By Region:
1. How big is the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market?
2. What is the demand of the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market?
3. What is the year over year growth of the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market?
4. What is the production and production value of the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market?
5. Who are the key producers in the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market?
6. What are the growth factors driving the market demand?
Ligand precursors for Ac 225 labeled PSMA targeted radiopharmaceuticals are high purity small molecule precursor materials used to manufacture prostate specific membrane antigen targeted alpha radiotherapeutics. The research scope focuses on non radioactive ligand compounds, clinical grade precursors and GMP grade precursors that can be chelated and labeled with actinium 225 for radiopharmaceutical production. These products are generally built from a PSMA binding motif, a molecular linker, a metal chelator and a radiolabeling ready functional structure. Main product forms include lyophilized precursor powder, standardized vial based precursor materials, custom synthesized intermediates and clinical batch precursors. Their production process involves multistep organic synthesis, peptide or peptidomimetic structure construction, chelator conjugation, impurity profiling, preparative purification, low bioburden control, stability testing and GMP documentation. Key specifications usually include chemical purity, individual impurity limits, residual solvents, water content, endotoxin, metal impurities, radiolabeling yield, radiochemical purity, identity confirmation and batch to batch consistency. The core function of these precursors is to provide nuclear medicine developers, radiopharmaceutical CDMOs, clinical research institutions and hospital nuclear medicine centers with reproducible and regulatory supportable starting materials for PSMA targeted alpha therapy manufacturing. Main applications are concentrated in clinical development and early commercial validation of targeted alpha radiopharmaceuticals for PSMA positive tumors, especially metastatic castration resistant prostate cancer. In 2025, the global average gross margin of ligand precursors for Ac 225 labeled PSMA targeted radiopharmaceuticals is estimated at about 55%.
Ligand precursors for Ac 225 labeled PSMA targeted radiopharmaceuticals represent a highly specialized upstream material segment within the radiopharmaceutical value chain. The upstream side includes actinium 225 radioisotope supply, chelators, protected amino acids, peptide synthesis inputs, GMP grade solvents and high purity reagents. The midstream layer covers PSMA ligand design, precursor synthesis, purification, analytical characterization, process scale up and clinical batch preparation. The downstream side consists of radiopharmaceutical developers, nuclear medicine CDMOs, hospital nuclear medicine centers and oncology clinical research networks. This product category should not be interpreted as a general research reagent or as a final therapeutic radiopharmaceutical. Its commercial value is concentrated in regulatory grade quality control, labeling compatibility with Ac 225, impurity management, stability data and the ability to support repeatable clinical manufacturing. Since Ac 225 PSMA targeted alpha therapy is still moving through clinical development, demand is currently driven mainly by GMP validation batches, clinical trial supply, custom synthesis and equivalent in house consumption by drug developers, rather than by full commercial scale drug manufacturing.
The competitive landscape remains narrow and concentrated. Only a small number of global suppliers can be reasonably identified as actual manufacturers of PSMA radioligand precursors with relevant production evidence, while a broader group of pharmaceutical companies and nuclear medicine platforms should be treated as pipeline owners rather than precursor manufacturers. Europe and the United States are the most important supply regions, supported by established radiopharmaceutical chemistry, GMP manufacturing know how and clinical trial infrastructure. China, Japan, South Korea and India have growing capabilities in peptide synthesis, pharmaceutical CDMO services and nuclear medicine development, but public evidence for stable production of Ac 225 compatible PSMA ligand precursors remains limited. Competition is less about bulk capacity and more about GMP readiness, analytical documentation, batch reproducibility, customer project linkage and intellectual property around ligand and chelator structures. Recent mergers and acquisitions in the radiopharmaceutical sector have strengthened the strategic importance of upstream precursor control and are gradually increasing clinical batch demand.
The policy environment is generally supportive, as major healthcare markets continue to encourage nuclear medicine, targeted radiotherapy, medical isotope supply and precision oncology infrastructure. However, the industry is still constrained by limited Ac 225 availability, radiopharmaceutical manufacturing licenses, transport restrictions, clinical development timelines and regulatory uncertainty. Future growth will mainly come from three sources: the advancement of PSMA targeted alpha therapy pipelines into later clinical stages, the gradual expansion of isotope supply that enables early commercial validation, and the development of next generation PSMA ligands with improved chelation stability, tumor retention and manufacturability. The market should therefore be viewed as a small scale but high value emerging segment. In the near term, it should not be benchmarked against the broader radiopharmaceutical drug market, but over the medium to long term it has strong strategic value because precursor quality, process reliability and supply security can directly affect clinical progress and commercialization readiness.
This report studies the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals total production and demand, 2021-2032, (kg)
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals total production value, 2021-2032, (USD Million)
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (kg), (based on production site)
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals consumption by region & country, CAGR, 2021-2032 & (kg)
U.S. VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals domestic production, consumption, key domestic manufacturers and share
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (kg)
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals production by Form, production, value, CAGR, 2021-2032, (USD Million) & (kg)
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals production by Application, production, value, CAGR, 2021-2032, (USD Million) & (kg)
This report profiles key players in the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include ABX Advanced Biochemical Compounds GmbH, Radnostix, Inc., JPT Peptide Technologies GmbH, SCINTOMICS Molecular, Applied Theranostics Technologies GmbH, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (kg) and average price (US$/kg) by manufacturer, by Form, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Lyophilized Precursor Powder
- Solution Form Precursor
- Others
- Research Grade
- Analytical Grade
- Clinical Grade
- GMP Grade
- Others
- PSMA 617 Based Precursors
- PSMA I&T Based Precursors
- Radiohybrid PSMA Precursors
- Bispecific or Multivalent PSMA Precursors
- Next Generation PSMA Precursors
- Others
- DOTA Based Chelator Precursors
- DOTAGA Based Chelator Precursors
- TCMC Based Chelator Precursors
- Macropa Based Chelator Precursors
- Others
- argeted Alpha Therapy
- Radiolabeling Process Development
- Clinical Trial Drug Manufacturing
- Quality Control and Reference Use
- Others
- ABX Advanced Biochemical Compounds GmbH
- Radnostix, Inc.
- JPT Peptide Technologies GmbH
- SCINTOMICS Molecular, Applied Theranostics Technologies GmbH
1. How big is the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market?
2. What is the demand of the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market?
3. What is the year over year growth of the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market?
4. What is the production and production value of the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market?
5. Who are the key producers in the global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Introduction
1.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Supply & Forecast
1.2.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value (2021 & 2025 & 2032)
1.2.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2032)
1.2.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Pricing Trends (2021-2032)
1.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Region (Based on Production Site)
1.3.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Region (2021-2032)
1.3.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Region (2021-2032)
1.3.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Region (2021-2032)
1.3.4 North America Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2032)
1.3.5 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Major Market Trends
2 DEMAND SUMMARY
2.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Demand (2021-2032)
2.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption by Region
2.2.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption by Region (2021-2026)
2.2.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Forecast by Region (2027-2032)
2.3 United States Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032)
2.4 China Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032)
2.5 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032)
2.6 Japan Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032)
2.7 South Korea Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032)
2.8 ASEAN Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032)
2.9 India Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Manufacturer (2021-2026)
3.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Manufacturer (2021-2026)
3.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Manufacturer (2021-2026)
3.4 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals in 2025
3.5.3 Global Concentration Ratios (CR8) for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals in 2025
3.6 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Overall Company Footprint Analysis
3.6.1 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Region Footprint
3.6.2 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Company Product Type Footprint
3.6.3 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Comparison
4.1.1 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Comparison
4.2.1 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Comparison
4.3.1 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value (2021-2026)
4.4.3 United States Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2026)
4.5 China Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers and Market Share
4.5.1 China Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value (2021-2026)
4.5.3 China Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2026)
4.6 Rest of World Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2026)
5 MARKET ANALYSIS BY FORM
5.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size Overview by Form: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Form
5.2.1 Lyophilized Precursor Powder
5.2.2 Solution Form Precursor
5.2.3 Others
5.3 Market Segment by Form
5.3.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Form (2021-2032)
5.3.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Form (2021-2032)
5.3.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Form (2021-2032)
6 MARKET ANALYSIS BY QUALITY GRADE
6.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size Overview by Quality Grade: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Quality Grade
6.2.1 Research Grade
6.2.2 Analytical Grade
6.2.3 Clinical Grade
6.2.4 GMP Grade
6.2.5 Others
6.3 Market Segment by Quality Grade
6.3.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Quality Grade (2021-2032)
6.3.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Quality Grade (2021-2032)
6.3.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Quality Grade (2021-2032)
7 MARKET ANALYSIS BY LIGAND PLATFORM
7.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size Overview by Ligand Platform: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Ligand Platform
7.2.1 PSMA 617 Based Precursors
7.2.2 PSMA I&T Based Precursors
7.2.3 Radiohybrid PSMA Precursors
7.2.4 Bispecific or Multivalent PSMA Precursors
7.2.5 Next Generation PSMA Precursors
7.2.6 Others
7.3 Market Segment by Ligand Platform
7.3.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Ligand Platform (2021-2032)
7.3.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Ligand Platform (2021-2032)
7.3.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Ligand Platform (2021-2032)
8 MARKET ANALYSIS BY CHELATOR SYSTEM
8.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size Overview by Chelator System: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Chelator System
8.2.1 DOTA Based Chelator Precursors
8.2.2 DOTAGA Based Chelator Precursors
8.2.3 TCMC Based Chelator Precursors
8.2.4 Macropa Based Chelator Precursors
8.2.5 Others
8.3 Market Segment by Chelator System
8.3.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Chelator System (2021-2032)
8.3.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Chelator System (2021-2032)
8.3.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Chelator System (2021-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 argeted Alpha Therapy
9.2.2 Radiolabeling Process Development
9.2.3 Clinical Trial Drug Manufacturing
9.2.4 Quality Control and Reference Use
9.2.5 Others
9.3 Market Segment by Application
9.3.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Application (2021-2032)
9.3.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Application (2021-2032)
9.3.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Application (2021-2032)
10 COMPANY PROFILES
10.1 ABX Advanced Biochemical Compounds GmbH
10.1.1 ABX Advanced Biochemical Compounds GmbH Details
10.1.2 ABX Advanced Biochemical Compounds GmbH Major Business
10.1.3 ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
10.1.4 ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.1.5 ABX Advanced Biochemical Compounds GmbH Recent Developments/Updates
10.1.6 ABX Advanced Biochemical Compounds GmbH Competitive Strengths & Weaknesses
10.2 Radnostix, Inc.
10.2.1 Radnostix, Inc. Details
10.2.2 Radnostix, Inc. Major Business
10.2.3 Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
10.2.4 Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.2.5 Radnostix, Inc. Recent Developments/Updates
10.2.6 Radnostix, Inc. Competitive Strengths & Weaknesses
10.3 JPT Peptide Technologies GmbH
10.3.1 JPT Peptide Technologies GmbH Details
10.3.2 JPT Peptide Technologies GmbH Major Business
10.3.3 JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
10.3.4 JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.3.5 JPT Peptide Technologies GmbH Recent Developments/Updates
10.3.6 JPT Peptide Technologies GmbH Competitive Strengths & Weaknesses
10.4 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH
10.4.1 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Details
10.4.2 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Major Business
10.4.3 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
10.4.4 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.4.5 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Recent Developments/Updates
10.4.6 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Industry Chain
11.2 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Upstream Analysis
11.2.1 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Core Raw Materials
11.2.2 Main Manufacturers of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Core Raw Materials
11.3 Midstream Analysis
11.4 Downstream Analysis
11.5 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Mode
11.6 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Procurement Model
11.7 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Industry Sales Model and Sales Channels
11.7.1 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Model
11.7.2 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Typical Distributors
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
1.1 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Introduction
1.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Supply & Forecast
1.2.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value (2021 & 2025 & 2032)
1.2.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2032)
1.2.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Pricing Trends (2021-2032)
1.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Region (Based on Production Site)
1.3.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Region (2021-2032)
1.3.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Region (2021-2032)
1.3.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Region (2021-2032)
1.3.4 North America Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2032)
1.3.5 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Major Market Trends
2 DEMAND SUMMARY
2.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Demand (2021-2032)
2.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption by Region
2.2.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption by Region (2021-2026)
2.2.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Forecast by Region (2027-2032)
2.3 United States Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032)
2.4 China Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032)
2.5 Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032)
2.6 Japan Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032)
2.7 South Korea Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032)
2.8 ASEAN Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032)
2.9 India Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Manufacturer (2021-2026)
3.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Manufacturer (2021-2026)
3.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Manufacturer (2021-2026)
3.4 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals in 2025
3.5.3 Global Concentration Ratios (CR8) for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals in 2025
3.6 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Overall Company Footprint Analysis
3.6.1 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Region Footprint
3.6.2 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Company Product Type Footprint
3.6.3 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Comparison
4.1.1 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Comparison
4.2.1 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Comparison
4.3.1 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value (2021-2026)
4.4.3 United States Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2026)
4.5 China Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers and Market Share
4.5.1 China Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value (2021-2026)
4.5.3 China Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2026)
4.6 Rest of World Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2026)
5 MARKET ANALYSIS BY FORM
5.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size Overview by Form: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Form
5.2.1 Lyophilized Precursor Powder
5.2.2 Solution Form Precursor
5.2.3 Others
5.3 Market Segment by Form
5.3.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Form (2021-2032)
5.3.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Form (2021-2032)
5.3.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Form (2021-2032)
6 MARKET ANALYSIS BY QUALITY GRADE
6.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size Overview by Quality Grade: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Quality Grade
6.2.1 Research Grade
6.2.2 Analytical Grade
6.2.3 Clinical Grade
6.2.4 GMP Grade
6.2.5 Others
6.3 Market Segment by Quality Grade
6.3.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Quality Grade (2021-2032)
6.3.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Quality Grade (2021-2032)
6.3.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Quality Grade (2021-2032)
7 MARKET ANALYSIS BY LIGAND PLATFORM
7.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size Overview by Ligand Platform: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Ligand Platform
7.2.1 PSMA 617 Based Precursors
7.2.2 PSMA I&T Based Precursors
7.2.3 Radiohybrid PSMA Precursors
7.2.4 Bispecific or Multivalent PSMA Precursors
7.2.5 Next Generation PSMA Precursors
7.2.6 Others
7.3 Market Segment by Ligand Platform
7.3.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Ligand Platform (2021-2032)
7.3.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Ligand Platform (2021-2032)
7.3.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Ligand Platform (2021-2032)
8 MARKET ANALYSIS BY CHELATOR SYSTEM
8.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size Overview by Chelator System: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Chelator System
8.2.1 DOTA Based Chelator Precursors
8.2.2 DOTAGA Based Chelator Precursors
8.2.3 TCMC Based Chelator Precursors
8.2.4 Macropa Based Chelator Precursors
8.2.5 Others
8.3 Market Segment by Chelator System
8.3.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Chelator System (2021-2032)
8.3.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Chelator System (2021-2032)
8.3.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Chelator System (2021-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 argeted Alpha Therapy
9.2.2 Radiolabeling Process Development
9.2.3 Clinical Trial Drug Manufacturing
9.2.4 Quality Control and Reference Use
9.2.5 Others
9.3 Market Segment by Application
9.3.1 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Application (2021-2032)
9.3.2 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Application (2021-2032)
9.3.3 World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Application (2021-2032)
10 COMPANY PROFILES
10.1 ABX Advanced Biochemical Compounds GmbH
10.1.1 ABX Advanced Biochemical Compounds GmbH Details
10.1.2 ABX Advanced Biochemical Compounds GmbH Major Business
10.1.3 ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
10.1.4 ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.1.5 ABX Advanced Biochemical Compounds GmbH Recent Developments/Updates
10.1.6 ABX Advanced Biochemical Compounds GmbH Competitive Strengths & Weaknesses
10.2 Radnostix, Inc.
10.2.1 Radnostix, Inc. Details
10.2.2 Radnostix, Inc. Major Business
10.2.3 Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
10.2.4 Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.2.5 Radnostix, Inc. Recent Developments/Updates
10.2.6 Radnostix, Inc. Competitive Strengths & Weaknesses
10.3 JPT Peptide Technologies GmbH
10.3.1 JPT Peptide Technologies GmbH Details
10.3.2 JPT Peptide Technologies GmbH Major Business
10.3.3 JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
10.3.4 JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.3.5 JPT Peptide Technologies GmbH Recent Developments/Updates
10.3.6 JPT Peptide Technologies GmbH Competitive Strengths & Weaknesses
10.4 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH
10.4.1 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Details
10.4.2 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Major Business
10.4.3 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
10.4.4 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production, Price, Value, Gross Margin and Market Share (2021-2026)
10.4.5 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Recent Developments/Updates
10.4.6 SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Industry Chain
11.2 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Upstream Analysis
11.2.1 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Core Raw Materials
11.2.2 Main Manufacturers of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Core Raw Materials
11.3 Midstream Analysis
11.4 Downstream Analysis
11.5 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Mode
11.6 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Procurement Model
11.7 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Industry Sales Model and Sales Channels
11.7.1 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Model
11.7.2 Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Typical Distributors
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
LIST OF TABLES
Table 1. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Region (2021-2026) & (USD Million)
Table 3. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Region (2027-2032) & (USD Million)
Table 4. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Region (2021-2026)
Table 5. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Region (2027-2032)
Table 6. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Region (2021-2026) & (kg)
Table 7. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Region (2027-2032) & (kg)
Table 8. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Region (2021-2026)
Table 9. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Region (2027-2032)
Table 10. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Region (2021-2026) & (US$/kg)
Table 11. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Region (2027-2032) & (US$/kg)
Table 12. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Major Market Trends
Table 13. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (kg)
Table 14. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption by Region (2021-2026) & (kg)
Table 15. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Forecast by Region (2027-2032) & (kg)
Table 16. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Producers in 2025
Table 18. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Manufacturer (2021-2026) & (kg)
Table 19. Production Market Share of Key Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Producers in 2025
Table 20. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Manufacturer (2021-2026) & (US$/kg)
Table 21. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Company Evaluation Quadrant
Table 22. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Site of Key Manufacturer
Table 24. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Company Product Type Footprint
Table 25. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Company Product Application Footprint
Table 26. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Competitive Factors
Table 27. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals New Entrant and Capacity Expansion Plans
Table 28. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Mergers & Acquisitions Activity
Table 29. United States VS China Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Comparison, (2021 & 2025 & 2032) & (kg)
Table 31. United States VS China Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Comparison, (2021 & 2025 & 2032) & (kg)
Table 32. United States Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2026) & (kg)
Table 36. United States Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share (2021-2026)
Table 37. China Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production, (2021-2026) & (kg)
Table 41. China Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share (2021-2026)
Table 42. Rest of World Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production, (2021-2026) & (kg)
Table 46. Rest of World Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share (2021-2026)
Table 47. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Form, (USD Million), 2021 & 2025 & 2032
Table 48. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Form (2021-2026) & (kg)
Table 49. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Form (2027-2032) & (kg)
Table 50. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Form (2021-2026) & (USD Million)
Table 51. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Form (2027-2032) & (USD Million)
Table 52. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Form (2021-2026) & (US$/kg)
Table 53. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Form (2027-2032) & (US$/kg)
Table 54. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Quality Grade, (USD Million), 2021 & 2025 & 2032
Table 55. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Quality Grade (2021-2026) & (kg)
Table 56. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Quality Grade (2027-2032) & (kg)
Table 57. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Quality Grade (2021-2026) & (USD Million)
Table 58. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Quality Grade (2027-2032) & (USD Million)
Table 59. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Quality Grade (2021-2026) & (US$/kg)
Table 60. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Quality Grade (2027-2032) & (US$/kg)
Table 61. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Ligand Platform, (USD Million), 2021 & 2025 & 2032
Table 62. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Ligand Platform (2021-2026) & (kg)
Table 63. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Ligand Platform (2027-2032) & (kg)
Table 64. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Ligand Platform (2021-2026) & (USD Million)
Table 65. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Ligand Platform (2027-2032) & (USD Million)
Table 66. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Ligand Platform (2021-2026) & (US$/kg)
Table 67. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Ligand Platform (2027-2032) & (US$/kg)
Table 68. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Chelator System, (USD Million), 2021 & 2025 & 2032
Table 69. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Chelator System (2021-2026) & (kg)
Table 70. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Chelator System (2027-2032) & (kg)
Table 71. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Chelator System (2021-2026) & (USD Million)
Table 72. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Chelator System (2027-2032) & (USD Million)
Table 73. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Chelator System (2021-2026) & (US$/kg)
Table 74. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Chelator System (2027-2032) & (US$/kg)
Table 75. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 76. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Application (2021-2026) & (kg)
Table 77. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Application (2027-2032) & (kg)
Table 78. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Application (2021-2026) & (USD Million)
Table 79. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Application (2027-2032) & (USD Million)
Table 80. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Application (2021-2026) & (US$/kg)
Table 81. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Application (2027-2032) & (US$/kg)
Table 82. ABX Advanced Biochemical Compounds GmbH Basic Information, Manufacturing Base and Competitors
Table 83. ABX Advanced Biochemical Compounds GmbH Major Business
Table 84. ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
Table 85. ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 86. ABX Advanced Biochemical Compounds GmbH Recent Developments/Updates
Table 87. ABX Advanced Biochemical Compounds GmbH Competitive Strengths & Weaknesses
Table 88. Radnostix, Inc. Basic Information, Manufacturing Base and Competitors
Table 89. Radnostix, Inc. Major Business
Table 90. Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
Table 91. Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 92. Radnostix, Inc. Recent Developments/Updates
Table 93. Radnostix, Inc. Competitive Strengths & Weaknesses
Table 94. JPT Peptide Technologies GmbH Basic Information, Manufacturing Base and Competitors
Table 95. JPT Peptide Technologies GmbH Major Business
Table 96. JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
Table 97. JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 98. JPT Peptide Technologies GmbH Recent Developments/Updates
Table 99. JPT Peptide Technologies GmbH Competitive Strengths & Weaknesses
Table 100. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Basic Information, Manufacturing Base and Competitors
Table 101. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Major Business
Table 102. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
Table 103. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 104. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Recent Developments/Updates
Table 105. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Competitive Strengths & Weaknesses
Table 106. Global Key Players of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Upstream (Raw Materials)
Table 107. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Typical Customers
Table 108. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Typical Distributors
Table 1. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Region (2021-2026) & (USD Million)
Table 3. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Region (2027-2032) & (USD Million)
Table 4. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Region (2021-2026)
Table 5. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Region (2027-2032)
Table 6. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Region (2021-2026) & (kg)
Table 7. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Region (2027-2032) & (kg)
Table 8. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Region (2021-2026)
Table 9. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Region (2027-2032)
Table 10. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Region (2021-2026) & (US$/kg)
Table 11. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Region (2027-2032) & (US$/kg)
Table 12. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Major Market Trends
Table 13. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (kg)
Table 14. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption by Region (2021-2026) & (kg)
Table 15. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Forecast by Region (2027-2032) & (kg)
Table 16. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Producers in 2025
Table 18. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Manufacturer (2021-2026) & (kg)
Table 19. Production Market Share of Key Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Producers in 2025
Table 20. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Manufacturer (2021-2026) & (US$/kg)
Table 21. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Company Evaluation Quadrant
Table 22. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Site of Key Manufacturer
Table 24. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Company Product Type Footprint
Table 25. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market: Company Product Application Footprint
Table 26. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Competitive Factors
Table 27. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals New Entrant and Capacity Expansion Plans
Table 28. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Mergers & Acquisitions Activity
Table 29. United States VS China Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Comparison, (2021 & 2025 & 2032) & (kg)
Table 31. United States VS China Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Comparison, (2021 & 2025 & 2032) & (kg)
Table 32. United States Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2026) & (kg)
Table 36. United States Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share (2021-2026)
Table 37. China Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production, (2021-2026) & (kg)
Table 41. China Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share (2021-2026)
Table 42. Rest of World Based Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production, (2021-2026) & (kg)
Table 46. Rest of World Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share (2021-2026)
Table 47. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Form, (USD Million), 2021 & 2025 & 2032
Table 48. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Form (2021-2026) & (kg)
Table 49. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Form (2027-2032) & (kg)
Table 50. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Form (2021-2026) & (USD Million)
Table 51. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Form (2027-2032) & (USD Million)
Table 52. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Form (2021-2026) & (US$/kg)
Table 53. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Form (2027-2032) & (US$/kg)
Table 54. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Quality Grade, (USD Million), 2021 & 2025 & 2032
Table 55. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Quality Grade (2021-2026) & (kg)
Table 56. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Quality Grade (2027-2032) & (kg)
Table 57. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Quality Grade (2021-2026) & (USD Million)
Table 58. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Quality Grade (2027-2032) & (USD Million)
Table 59. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Quality Grade (2021-2026) & (US$/kg)
Table 60. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Quality Grade (2027-2032) & (US$/kg)
Table 61. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Ligand Platform, (USD Million), 2021 & 2025 & 2032
Table 62. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Ligand Platform (2021-2026) & (kg)
Table 63. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Ligand Platform (2027-2032) & (kg)
Table 64. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Ligand Platform (2021-2026) & (USD Million)
Table 65. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Ligand Platform (2027-2032) & (USD Million)
Table 66. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Ligand Platform (2021-2026) & (US$/kg)
Table 67. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Ligand Platform (2027-2032) & (US$/kg)
Table 68. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Chelator System, (USD Million), 2021 & 2025 & 2032
Table 69. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Chelator System (2021-2026) & (kg)
Table 70. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Chelator System (2027-2032) & (kg)
Table 71. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Chelator System (2021-2026) & (USD Million)
Table 72. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Chelator System (2027-2032) & (USD Million)
Table 73. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Chelator System (2021-2026) & (US$/kg)
Table 74. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Chelator System (2027-2032) & (US$/kg)
Table 75. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 76. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Application (2021-2026) & (kg)
Table 77. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production by Application (2027-2032) & (kg)
Table 78. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Application (2021-2026) & (USD Million)
Table 79. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Application (2027-2032) & (USD Million)
Table 80. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Application (2021-2026) & (US$/kg)
Table 81. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Application (2027-2032) & (US$/kg)
Table 82. ABX Advanced Biochemical Compounds GmbH Basic Information, Manufacturing Base and Competitors
Table 83. ABX Advanced Biochemical Compounds GmbH Major Business
Table 84. ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
Table 85. ABX Advanced Biochemical Compounds GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 86. ABX Advanced Biochemical Compounds GmbH Recent Developments/Updates
Table 87. ABX Advanced Biochemical Compounds GmbH Competitive Strengths & Weaknesses
Table 88. Radnostix, Inc. Basic Information, Manufacturing Base and Competitors
Table 89. Radnostix, Inc. Major Business
Table 90. Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
Table 91. Radnostix, Inc. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 92. Radnostix, Inc. Recent Developments/Updates
Table 93. Radnostix, Inc. Competitive Strengths & Weaknesses
Table 94. JPT Peptide Technologies GmbH Basic Information, Manufacturing Base and Competitors
Table 95. JPT Peptide Technologies GmbH Major Business
Table 96. JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
Table 97. JPT Peptide Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 98. JPT Peptide Technologies GmbH Recent Developments/Updates
Table 99. JPT Peptide Technologies GmbH Competitive Strengths & Weaknesses
Table 100. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Basic Information, Manufacturing Base and Competitors
Table 101. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Major Business
Table 102. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Product and Services
Table 103. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (kg), Price (US$/kg), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 104. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Recent Developments/Updates
Table 105. SCINTOMICS Molecular, Applied Theranostics Technologies GmbH Competitive Strengths & Weaknesses
Table 106. Global Key Players of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Upstream (Raw Materials)
Table 107. Global Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Typical Customers
Table 108. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Typical Distributors
LIST OF FIGURES
Figure 1. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Picture
Figure 2. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2032) & (kg)
Figure 5. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price (2021-2032) & (US$/kg)
Figure 6. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Region (2021-2032)
Figure 7. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Region (2021-2032)
Figure 8. North America Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2032) & (kg)
Figure 9. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2032) & (kg)
Figure 10. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Drivers
Figure 11. Factors Affecting Demand
Figure 12. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 13. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Market Share by Region (2021-2032)
Figure 14. United States Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 15. China Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 16. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 17. Japan Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 18. South Korea Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 19. ASEAN Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 20. India Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 21. Producer Shipments of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 22. Global Four-firm Concentration Ratios (CR4) for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Markets in 2025
Figure 23. Global Four-firm Concentration Ratios (CR8) for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Markets in 2025
Figure 24. United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 25. United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share Comparison (2021 & 2025 & 2032)
Figure 26. United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share 2025
Figure 28. China Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share 2025
Figure 29. Rest of World Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share 2025
Figure 30. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Form, (USD Million), 2021 & 2025 & 2032
Figure 31. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Form in 2025
Figure 32. Lyophilized Precursor Powder
Figure 33. Solution Form Precursor
Figure 34. Others
Figure 35. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Form (2021-2032)
Figure 36. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Form (2021-2032)
Figure 37. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Form (2021-2032) & (US$/kg)
Figure 38. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Quality Grade, (USD Million), 2021 & 2025 & 2032
Figure 39. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Quality Grade in 2025
Figure 40. Research Grade
Figure 41. Analytical Grade
Figure 42. Clinical Grade
Figure 43. GMP Grade
Figure 44. Others
Figure 45. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Quality Grade (2021-2032)
Figure 46. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Quality Grade (2021-2032)
Figure 47. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Quality Grade (2021-2032) & (US$/kg)
Figure 48. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Ligand Platform, (USD Million), 2021 & 2025 & 2032
Figure 49. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Ligand Platform in 2025
Figure 50. PSMA 617 Based Precursors
Figure 51. PSMA I&T Based Precursors
Figure 52. Radiohybrid PSMA Precursors
Figure 53. Bispecific or Multivalent PSMA Precursors
Figure 54. Next Generation PSMA Precursors
Figure 55. Others
Figure 56. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Ligand Platform (2021-2032)
Figure 57. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Ligand Platform (2021-2032)
Figure 58. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Ligand Platform (2021-2032) & (US$/kg)
Figure 59. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Chelator System, (USD Million), 2021 & 2025 & 2032
Figure 60. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Chelator System in 2025
Figure 61. DOTA Based Chelator Precursors
Figure 62. DOTAGA Based Chelator Precursors
Figure 63. TCMC Based Chelator Precursors
Figure 64. Macropa Based Chelator Precursors
Figure 65. Others
Figure 66. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Chelator System (2021-2032)
Figure 67. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Chelator System (2021-2032)
Figure 68. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Chelator System (2021-2032) & (US$/kg)
Figure 69. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 70. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Application in 2025
Figure 71. argeted Alpha Therapy
Figure 72. Radiolabeling Process Development
Figure 73. Clinical Trial Drug Manufacturing
Figure 74. Quality Control and Reference Use
Figure 75. Others
Figure 76. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Application (2021-2032)
Figure 77. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Application (2021-2032)
Figure 78. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Application (2021-2032) & (US$/kg)
Figure 79. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Industry Chain
Figure 80. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Procurement Model
Figure 81. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Model
Figure 82. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Channels, Direct Sales, and Distribution
Figure 83. Methodology
Figure 84. Research Process and Data Source
Figure 1. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Picture
Figure 2. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2032) & (kg)
Figure 5. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price (2021-2032) & (US$/kg)
Figure 6. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Region (2021-2032)
Figure 7. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Region (2021-2032)
Figure 8. North America Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2032) & (kg)
Figure 9. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production (2021-2032) & (kg)
Figure 10. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Market Drivers
Figure 11. Factors Affecting Demand
Figure 12. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 13. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Market Share by Region (2021-2032)
Figure 14. United States Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 15. China Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 16. Europe Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 17. Japan Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 18. South Korea Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 19. ASEAN Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 20. India Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption (2021-2032) & (kg)
Figure 21. Producer Shipments of Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 22. Global Four-firm Concentration Ratios (CR4) for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Markets in 2025
Figure 23. Global Four-firm Concentration Ratios (CR8) for Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Markets in 2025
Figure 24. United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 25. United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share Comparison (2021 & 2025 & 2032)
Figure 26. United States VS China: Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share 2025
Figure 28. China Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share 2025
Figure 29. Rest of World Based Manufacturers Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share 2025
Figure 30. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Form, (USD Million), 2021 & 2025 & 2032
Figure 31. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Form in 2025
Figure 32. Lyophilized Precursor Powder
Figure 33. Solution Form Precursor
Figure 34. Others
Figure 35. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Form (2021-2032)
Figure 36. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Form (2021-2032)
Figure 37. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Form (2021-2032) & (US$/kg)
Figure 38. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Quality Grade, (USD Million), 2021 & 2025 & 2032
Figure 39. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Quality Grade in 2025
Figure 40. Research Grade
Figure 41. Analytical Grade
Figure 42. Clinical Grade
Figure 43. GMP Grade
Figure 44. Others
Figure 45. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Quality Grade (2021-2032)
Figure 46. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Quality Grade (2021-2032)
Figure 47. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Quality Grade (2021-2032) & (US$/kg)
Figure 48. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Ligand Platform, (USD Million), 2021 & 2025 & 2032
Figure 49. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Ligand Platform in 2025
Figure 50. PSMA 617 Based Precursors
Figure 51. PSMA I&T Based Precursors
Figure 52. Radiohybrid PSMA Precursors
Figure 53. Bispecific or Multivalent PSMA Precursors
Figure 54. Next Generation PSMA Precursors
Figure 55. Others
Figure 56. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Ligand Platform (2021-2032)
Figure 57. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Ligand Platform (2021-2032)
Figure 58. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Ligand Platform (2021-2032) & (US$/kg)
Figure 59. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Chelator System, (USD Million), 2021 & 2025 & 2032
Figure 60. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Chelator System in 2025
Figure 61. DOTA Based Chelator Precursors
Figure 62. DOTAGA Based Chelator Precursors
Figure 63. TCMC Based Chelator Precursors
Figure 64. Macropa Based Chelator Precursors
Figure 65. Others
Figure 66. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Chelator System (2021-2032)
Figure 67. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Chelator System (2021-2032)
Figure 68. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Chelator System (2021-2032) & (US$/kg)
Figure 69. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 70. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Application in 2025
Figure 71. argeted Alpha Therapy
Figure 72. Radiolabeling Process Development
Figure 73. Clinical Trial Drug Manufacturing
Figure 74. Quality Control and Reference Use
Figure 75. Others
Figure 76. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Market Share by Application (2021-2032)
Figure 77. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Production Value Market Share by Application (2021-2032)
Figure 78. World Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Average Price by Application (2021-2032) & (US$/kg)
Figure 79. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Industry Chain
Figure 80. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Procurement Model
Figure 81. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Model
Figure 82. Ligand Precursors for Ac-225-Labeled PSMA Targeted Radiopharmaceuticals Sales Channels, Direct Sales, and Distribution
Figure 83. Methodology
Figure 84. Research Process and Data Source
